These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 23912625

  • 1. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL.
    Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
    [Abstract] [Full Text] [Related]

  • 2. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 3. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
    Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):899-910. PubMed ID: 16510744
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Mar 02; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 05; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 05; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S, Comar M, Ferrante P.
    Immunotherapy; 2017 Jan 05; 9(2):157-171. PubMed ID: 28004598
    [Abstract] [Full Text] [Related]

  • 9. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul 05; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 05; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab for the treatment of relapsing multiple sclerosis.
    Rudick RA, Panzara MA.
    Biologics; 2008 Jun 05; 2(2):189-99. PubMed ID: 19707353
    [Abstract] [Full Text] [Related]

  • 12. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Jun 05; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 13. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 14. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A, Pilz G, Einhaeupl M, Oppermann K, Hitzl W, Wipfler P, Sellner J, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J.
    PLoS One; 2012 Jul 12; 7(2):e31784. PubMed ID: 22363732
    [Abstract] [Full Text] [Related]

  • 15. CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study.
    Häusler D, Akgün K, Stork L, Lassmann H, Ziemssen T, Brück W, Metz I.
    Brain Pathol; 2021 Nov 12; 31(6):e12969. PubMed ID: 33955606
    [Abstract] [Full Text] [Related]

  • 16. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A, Steinman L.
    Curr Neurol Neurosci Rep; 2006 May 12; 6(3):253-8. PubMed ID: 16635435
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 12; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 19. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D.
    Curr Med Res Opin; 2014 Apr 02; 30(4):629-35. PubMed ID: 24289170
    [Abstract] [Full Text] [Related]

  • 20. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.